Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04385290 |
|
Recruitment Status :
Recruiting
First Posted : May 12, 2020
Last Update Posted : December 1, 2022
|
Sponsor:
Technische Universität Dresden
Collaborators:
Novartis Pharmaceuticals
Pfizer
Information provided by (Responsible Party):
Technische Universität Dresden
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 2027 |
| Estimated Study Completion Date : | April 2028 |